Clinical and treatment patterns of advanced and radioiodine-refractory differentiated thyroid cancer. ERUDIT study
Por:
Lopez, CL, Sambo, M, Orcajo-Rincon, L, Durán-Poveda, M, García, JRV, Santos, RJ, Muñoz, ML, Navarro-González, E, Aller, J, Pubul, V, Guadalix, S, Crespo, G, González, C, Zafon, C, Navarro, M, Sandi, JS, Segura, A, Gajate, P, Gomez-Balaguer, M, Valdivia, J, Reverter, JL, Galofré, JC, Castelo, B, Villanueva, MJ, Argüelles, I and Casas, JAV
Publicada:
1 may 2026
Ahead of Print:
1 nov 2025
Resumen:
BackgroundR adioiodine-refractory (RR) disease drives morbidity and mortality in advanced differentiated thyroid cancer (aDTC) and yet real-world longitudinal data from the Iberian Peninsula are sparse. Objectives To characterize clinical features, multidisciplinary management, and outcomes of RR-DTC within a multicenter Iberian cohort, and to explore prognostic factors, including the impact of de novo versus recurrent/progressive presentation. Methods Multicenter, retrospective cohort of adults with aDTC diagnosed in 2007-2012 at 23 Spanish/Portuguese centers, with follow-up until 2017. Baseline demographic and clinical characteristics, local/systemic treatments used, progression-free survival (PFS) on first-line systemic therapy (ST), overall survival (OS) from RR-DTC, and survival prognostic factors were assessed. An exploratory illness-death multistate Markov model complemented Kaplan-Meier analyses for mortality from initial diagnosis. Missing data were not imputed. Results Of 213 aDTC patients, 165 (77.5%) met >= 1 RR-DTC criterion at any time during their follow-up. At RR-DTC diagnosis, ECOG was recorded in 92/165 (55.8%): 75 (81.5%) ECOG 0-1 and 17 (18.5%) ECOG 2-4. Management included watchful waiting (WW) in 79/165 (47.9%), locoregional therapy in 83/165 (50.3%), and ST in 61/165 (37.0%), predominantly sorafenib. Median PFS on first-line ST was 16.0 months (95% CI 9.2-29.9). Median OS from RR-DTC diagnosis was 4.7 years (3.4-8.0), shorter for de novo aDTC versus recurrent/progressive eDTC (3.0 vs 8.0 years; log-rank p < 0.0001). In multivariable analyses, age < 55 years and WW >= 30 months were associated with longer OS, while de novo aDTC and ECOG 2-4 were associated with higher mortality. From initial DTC diagnosis, the multistate model showed higher cumulative mortality for RR-DTC versus non-RR-DTC (HR 3.22; p < 0.001). Conclusions In this Iberian cohort, RR-DTC was frequent and often managed within MDTs, with substantial WW use. De novo aDTC and poor performance status were associated with worse survival. Prolonged WW appeared associated with longer OS, but this likely reflects selection and lead/immortal-time biases underscoring the need for prospective validation.
Filiaciones:
Lopez, CL:
UNICAN, Marques Valdecilla Univ Hosp, IDIVAL, Dept Med Oncol, Avda Valdecilla 28, Santander 39008, Cantabria, Spain
Sambo, M:
Gregorio Maranon Univ Hosp, Dept Endocrinol, Madrid, Spain
Orcajo-Rincon, L:
Clin Evidence Generat Eisai Farmaceut SA, DHBL Oncol, Madrid, Spain
Durán-Poveda, M:
Rey Juan Carlos Univ Hosp, Dept Gen & Digest Surg, Madrid, Spain
García, JRV:
Clin Evidence Generat Eisai Farmaceut SA, DHBL Oncol, Madrid, Spain
Santos, RJ:
Hosp CUF Cascais, Dept Endocrinol, Cascais, Portugal
Muñoz, ML:
Hosp Univ Canarias, Dept Med Oncol, San Cristobal la Laguna, Santa Cruz de T, Spain
Navarro-González, E:
Virgen Rocio Univ Hosp, Dept Endocrinol, Seville, Spain
Aller, J:
Puerta Hierro Majadahonda Univ Hosp, Dept Endocrinol, Madrid, Spain
Pubul, V:
Univ Hosp & Hlth Res Inst Santiago Compostela, Dept Nucl Med, Santiago De Compostela, Spain
Guadalix, S:
Hosp Univ 12 Octubre, Dept Endocrinol & Nutr, Madrid, Spain
Crespo, G:
Burgos Univ Hosp, Dept Med Oncol, Burgos, Spain
González, C:
CIBER BBN, Consortium Gen Univ Hosp, Dept Endocrinol & Nutr, Valencia, Spain
Zafon, C:
Vall Hebron Univ Hosp, Dept Endocrinol & Nutr, Barcelona, Spain
Autonomous Univ Barcelona UAB, Barcelona, Spain
Navarro, M:
Univ Hosp Salamanca, Dept Med Oncol, Salamanca, Spain
Sandi, JS:
Cruces Univ Hosp, Dept Endocrinol, Vizcaya, Spain
Segura, A:
La Fe Univ & Politecn Hosp, Dept Med Oncol Unit, Valencia, Spain
Gajate, P:
Ramon & Cajal Univ Hosp, Dept Med Oncol, Madrid, Spain
Gomez-Balaguer, M:
Doctor Peset Univ Hosp, Dept Endocrinol, Valencia, Spain
Valdivia, J:
Univ Hosp Ctr Virgen Las Nieves, Dept Oncol, Granada, Spain
:
Hlth Sci Res Inst & Univ Hosp Germans Trias I Pujo, Endocrine & Nutr Serv, Badalona, Spain
Galofré, JC:
Univ Navarra, Clin Univ Navarra, Dept Endocrinol, Pamplona, Spain
Castelo, B:
La Paz Univ Hosp, Dept Med Oncol, Madrid, Spain
Villanueva, MJ:
Univ Vigo, Alvaro Cunqueiro Univ Hosp Complex, Dept Med Oncol, Vigo, Spain
Argüelles, I:
Son Espases Univ Hosp, Dept Endocrinol & Nutr, Palma De Mallorca, Spain
Casas, JAV:
Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Inst Biomed Res Cordoba IMIBIC, Dept Nucl Med UGC, Cordoba, Spain
Green Submitted, hybrid
|